Bio-Techne Corp (NASDAQ: TECH) has experienced a rise in its stock price by 1.80 compared to its previous closing price of 57.35. However, the company has seen a fall of -1.68% in its stock price over the last five trading days. prnewswire.com reported 2025-04-02 that MINNEAPOLIS, April 2, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD’s new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica’s BOND RX research staining instrument, further advancing the capabilities of spatial biology research.
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
Bio-Techne Corp (NASDAQ: TECH) has a higher price-to-earnings ratio of 59.34x compared to its average ratio, The 36-month beta value for TECH is at 1.44. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for TECH is 156.31M, and currently, shorts hold a 4.01% of that float. The average trading volume for TECH on April 03, 2025 was 1.59M shares.
TECH’s Market Performance
TECH stock saw a decrease of -1.68% in the past week, with a monthly decline of -2.89% and a quarterly a decrease of -19.24%. The volatility ratio for the week is 3.17%, and the volatility levels for the last 30 days are 3.92% for Bio-Techne Corp (TECH).. The simple moving average for the past 20 days is -3.67% for TECH’s stock, with a -19.07% simple moving average for the past 200 days.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Evercore ISI repeating the rating for TECH by listing it as a “Outperform.” The predicted price for TECH in the upcoming period, according to Evercore ISI is $75 based on the research report published on March 18, 2025 of the current year 2025.
Robert W. Baird, on the other hand, stated in their research note that they expect to see TECH reach a price target of $68, previously predicting the price at $88. The rating they have provided for TECH stocks is “Neutral” according to the report published on February 19th, 2025.
Citigroup gave a rating of “Neutral” to TECH, setting the target price at $85 in the report published on May 22nd of the previous year.
TECH Trading at -11.06% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.78% of loss for the given period.
Volatility was left at 3.92%, however, over the last 30 days, the volatility rate increased by 3.17%, as shares sank -6.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.87% lower at present.
During the last 5 trading sessions, TECH fell by -1.68%, which changed the moving average for the period of 200-days by -24.06% in comparison to the 20-day moving average, which settled at $60.61. In addition, Bio-Techne Corp saw -18.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from Herr Amy E., who sale 1,860 shares at the price of $65.96 back on Feb 14 ’25. After this action, Herr Amy E. now owns 1,976 shares of Bio-Techne Corp, valued at $122,691 using the latest closing price.
JOSHUA MOLHO, the Domestic Partner of Director of Bio-Techne Corp, proposed sale 1,860 shares at $65.96 during a trade that took place back on Feb 14 ’25, which means that JOSHUA MOLHO is holding shares at $122,691 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.66 for the gross margin
The net margin for Bio-Techne Corp stands at 0.13. The total capital return value is set at 0.1. Equity return is now at value 7.82, with 5.85 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.77. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 21.99.
Currently, EBITDA for the company is 310.37 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 7.9. The receivables turnover for the company is 5.49for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.94.
Conclusion
In conclusion, Bio-Techne Corp (TECH) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
